Normativa SEPAR sobre estadificación del cáncer de pulmón

While evidence for lung cancer screening implementation in Europe is awaited, Rapid Diagnostic Units have been established in many hospitals to accelerate the early diagnosis of lung cancer. We seek to develop an algorithm to detect lung cancer in a symptomatic population attending such unit, based on a sensitive serum marker panel. Serum concentrations of Epidermal Growth Factor, sCD26, Calprotectin, Matrix Metalloproteinases −1, −7, −9, CEA and CYFRA 21.1 were determined in 140 patients with respiratory symptoms (lung cancer and controls with/without benign pathology). Logistic Lasso regression was performed to derive a lung cancer prediction model, and the resulting algorithm was tested in a validation set. A classification rule based on EGF, sCD26, Calprotectin and CEA was established, able to reasonably discriminate lung cancer with 97% sensitivity and 43% specificity in the training set, and 91.7% sensitivity and 45.4% specificity in the validation set. Overall, the panel identified with high sensitivity stage I non-small cell lung cancer (94.7%) and 100% small-cell lung cancers. Our study provides a sensitive 4-marker classification algorithm for lung cancer detection to aid in the management of suspicious lung cancer patients in the context of Rapid Diagnostic Units.

show abstract

“…Histological assessment of tumours followed the WHO criteria35 and staging was performed according to the 7 th edition of TNM36.…”

Section: Methodsmentioning

confidence: 99%

Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units

Blanco-Prieto

Chiara

Rodríguez-Girondo

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The present accepted guidelines for pathological and staging diagnosis of lung cancer were used [31]. The most frequent diagnostic was squamous cell carcinoma (21 patients, 51 %), followed by adenocarcinoma (eight patients, 19.5 %), small cell carcinoma (seven patients, 17 %), and large cell carcinoma (two patients, 4.8 %).…”

Section: Instruments and Apparatusmentioning

confidence: 99%

Human sweat metabolomics for lung cancer screening

et al. 2015

View full text Add to dashboard Cite

Sweat is one of the less employed biofluids for discovery of markers in spite of its increased application in medicine for detection of drugs or for diagnostic of cystic fibrosis. In this research, human sweat was used as clinical sample to develop a screening tool for lung cancer, which is the carcinogenic disease with the highest mortality rate owing to the advanced stage at which it is usually detected. In this context, a method based on the metabolite analysis of sweat to discriminate between patients with lung cancer versus smokers as control individuals is proposed. The capability of the metabolites identified in sweat to discriminate between both groups of individuals was studied and, among them, a trisaccharide phosphate presented the best independent performance in terms of the specificity/sensitivity pair (80 and 72.7%, respectively). Additionally, two panels of metabolites were configured using the PanelomiX tool as an attempt to reduce false negatives (at least 80% specificity) and false positives (at least 80% sensitivity). The first panel (80% specificity and 69% sensitivity) was composed by suberic acid, a tetrahexose, and a trihexose, while the second panel (69% specificity and 80% sensitivity) included nonanedioic acid, a trihexose, and the monoglyceride MG(22:2). Thus, the combination of the five metabolites led to a single panel providing 80% specificity and 79% sensitivity, reducing the false positive and negative rates to almost 20%. The method was validated by estimation of within-day and between-days variability of the quantitative analysis of the five metabolites

show abstract

“…indications of mediastinoscopy, 62 and it no longer occupies the first step in mediastinal staging algorithms 31,30,63 (Fig. 2).…”

Section: Surgical Techniquesmentioning

confidence: 99%

Executive Summary of the SEPAR Recommendations for the Diagnosis and Treatment of Non-small Cell Lung Cancer

Álvarez

Trueba²,

Sanchis

et al. 2016

Archivos de Bronconeumología (English Edition)

View full text Add to dashboard Cite

Normativa SEPAR sobre estadificación del cáncer de pulmón

Cited by 51 publications

References 63 publications

Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units

Highly Sensitive Marker Panel for Guidance in Lung Cancer Rapid Diagnostic Units

Human sweat metabolomics for lung cancer screening

Executive Summary of the SEPAR Recommendations for the Diagnosis and Treatment of Non-small Cell Lung Cancer

Contact Info

Product

Resources

About